Taiwan AI Labs and GE Healthcare announced a joint alliance on 27 March to integrate DeepMets, an artificial intelligence image analysis system for brain metastases, into the clinical application of MRI images to help physicians accelerate the treatment process.

As the ChatGPT sends shockwaves across the board, it is an irreversible trend to combine medical technology with artificial intelligence. In the short term, it is hoped that the future will be through GE's worldwide distribution channels.

According to Ethan Tu, founder of Taiwan AI Labs, DeepMets already has many international partners and has been looking forward to more extensive clinical applications in Taiwan. This collaboration with GE Taiwan is the best opportunity to combine artificial intelligence models with MRI systems and bring them into the Taiwanese medical field to improve the diagnosis process of brain metastases.

According to GE in Taiwan, the Taiwan AI Lab has cutting-edge AI technology to train the localised medical data used by DeepMets, and promotes Federated learning to protect human rights and privacy. This decentralised approach enables the training of AI models using over 3,000 images from 23 medical centres without taking the data out of the hospital.

Metastatic cancer is the most prevalent of all brain cancers, yet the location and size of the tumours are so diverse that diagnosis and treatment of the disease has been challenging. DeepMets not only accelerates the development of treatment strategies for 66% of lung cancer patients, effectively shortening the consultation process and reducing the anxiety and fear faced by patients' families while waiting for treatment, but also offers great accuracy and sensitivity.

DeepMets is the world's first in the field of brain metastases, with a sensitivity of 85% for 4-mm tumours and 97% for 10-mm tumours, compared to other AI models for brain metastases. DeepMets is the world's first in the field of brain metastases.

DeepMets was jointly developed by Taiwan AI Labs and Taipei Veterans General Hospital, and its subsidiary TAIMedImg has been certified by Taiwan's FDA as a SaMD (Software for Medical Devices) since September 2022, making it the first homegrown product to obtain TFDA approval for magnetic vibration medical imaging AI.